FDA may have to moderate its data expectations for providing clinical validity of laboratory-developed tests if its newly planned framework is going to be feasible to implement, speakers at a Sept. 18 diagnostics policy conference said.
The framework would subject makers of LDTs, which are diagnostic services offered from the same lab in which the test is developed, to FDA premarket and postmarket regulatory...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?